Future gazing in the management of multiply drug-resistant Gram-positive infection

Journal of Infection

Volumn 59, Issue SUPPL. 1, 2009, Pages

  Wilcox, Mark H ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Antimicrobial selection; Gram positive bacteria; Guidelines; Linezolid; MRSA; Multidrug resistance

Indexed keywords

CEPHALOSPORIN; CLINDAMYCIN; DAPTOMYCIN; FUSIDIC ACID; LINEZOLID; PLACEBO; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CROSS RESISTANCE; DRUG CHOICE; DRUG INDICATION; DRUG SAFETY; ENDEMIC DISEASE; GENETIC POLYMORPHISM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NEUROPATHY; NONHUMAN; PERIOPERATIVE PERIOD; PNEUMONIA; POSTMARKETING SURVEILLANCE; RISK REDUCTION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDEMIC DISEASES; FORECASTING; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PERIOPERATIVE CARE;

EID: 70249094757     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(09)60010-4     Document Type: Article

References (30)

1. European Antimicrobial Resistance Surveillance System Annual Report 2004. Available at: http://www.rivm.nl/earss/Images/EARSS%20annual%20report%202004%20webvers ie_tcm61-25345.pdf Accessed September 9, 2008.
2. European Antimicrobial Resistance Surveillance System Annual Report 2002. Available at: http://www.rivm.nl/earss/Images/Earss%20nieuw%20totaal_tcm61-25028.pdf Accessed September 9, 2008.
3. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
4. Brown E.M., and Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 55 (2005) 6-9
5. Gemmell C.G., Edwards D.I., Fraise A.P., Gould F.K., Ridgway G.L., Warren R.E., Joint Working Party of the British Society for Antimicrobial Chemotherapy, and Hospital Infection Society and Infection Control Nurses Association. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57 (2006) 589-608
6. Miller K., O'Neill A.J., Wilcox M.H., Ingham E., and Chopra I. Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother 52 (2008) 1940-1944
7. Cui L., Tominaga E., Neoh H.M., and Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1079-1082
8. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering Jr. R.C., and Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 (2006) 1581-1585
9. Palenzuela L., Hahn N.M., Nelson Jr. R.P., et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?. Clin Infect Dis 40 (2005) 113-116
10. McKee E.E., Ferguson M., Bentley A.T., and Marks T.A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50 (2006) 2042-2049
11. Haley R.W. The scientific basis for using surveillance and risk factor data to reduce nosocomial infection rates. J Hosp Infect 30 Suppl (1995) 3-14
12. Health Protection Agency. Mandatory Surveillance of Healthcare Associated Infections Report 2006. Originally available at: http://www.hpa.org.uk/infections/topics_az/hai/Mandatory_Surveillance_of_Healthcare_Associated_Infection_Report_2006.pdf Also available at: http://news.bbc.co.uk/1/shared/bsp/hi/pdfs/24_07_06_infections.pdf. Accessed September 9, 2008.
13. Health Protection Agency. Mandatory Staphylococcus aureus bacteraemia surveillance scheme. Available at: http://www.hpa.org.uk/webw/HPAweb&Page&HPAwebAutoListName/Page/1 191942169773?p=1191942169773 Accessed January 24, 2009.
14. Loveday H.P., Pellowe C.M., Jones S.R., and Pratt R.J. A systematic review of the evidence for interventions for the prevention and control of methicillinresistant Staphylococcus aureus (1996 2004): report to the Joint MRSA Working Party (Subgroup A). J Hosp Infect 63 Suppl 1 (2006) S45-S70
15. Harbarth S., Masuet-Aumatell C., Schrenzel J., et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care 10 (2006) R25
16. Jeyaratnam D., Whitty C.J., Phillips K., Liu D., Orezzi C., Ajoku U., and French G.L. Impact of rapid screening tests on acquisition of meticillin resistant Staphylococcus aureus: cluster randomised crossover trial. BMJ 336 (2008) 927-930
17. Harbarth S., Fankhauser C., Schrenzel J., Christenson J., Gervaz P., Bandiera-Clerc C., Renzi G., Vernaz N., Sax H., and Pittet D. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 299 (2008) 1149-1157
18. Robicsek A., Beaumont J.L., Paule S.M., Hacek D.M., Thomson Jr. R.B., Kaul K.L., King P., and Peterson L.R. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 148 (2008) 409-418
19. Wilcox M.H., Hall J., Pike H., et al. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J Hosp Infect 54 (2003) 196-201
20. Cimochowski G.E., Harostock M.D., Brown R., Bernardi M., Alonzo N., and Coyle K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 71 (2001) 1572-1578
21. Kalmeijer M.D., Coertjens H., van Nieuwland-Bollen P.M., et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 35 (2002) 353-358
22. Fawley W.N., Parnell P., Hall J., and Wilcox M.H. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. J Hosp Infect 62 (2006) 327-332
23. Miller M.A., Dascal A., Portnoy J., and Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 17 (1996) 811-813
24. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant Gram-positive cocci. Antimicrob Agents Chemother 50 (2006) 2583-2586
25. Naderer OJ, Anderson M, Roberts K, Lou Y, Zhu J, Min S, Scangarella N, Shawar, R. Nasal decolonization of persistent Staphylococcus aureus carriers with twice daily retapamulin treatment for 3 or 5 days. 48th ICAAC/46th IDSA Annual Meeting, Washington, DC, October 25 28,2008. Abstract L-1492.
26. Wilcox M.H. Antibiotic prescribing as a risk factor for MRSA. Hosp Med 66 (2005) 180-184
27. Charbonneau P., Parienti J.J., Thibon P., et al., French Fluoroquinolone Free (3F) Study Group. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 42 (2006) 778-784
28. Gee T., Ellis R., Marshall G., Andrews J., Ashby J., and Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45 (2001) 1843-1846
29. Cepeda J.A., Whitehouse T., Cooper B., et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53 (2004) 345-355
30. Ferrer L, de Otero J, Elia S, Sandiumenge M, Montull E, Ferrer-Ruscalleda F. Linezolid in the treatment of methicillin-resistant Staphylococcus aureus infection. Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Milan, Italy; 2002; Abstract O-138.